COVID-19 Shifts ICER Pricing Targets, Creating New Hurdles For Drug Developers

 
• By Sarah Karlin-Smith
  
Cost effective check approval sign concept illustration design graphic
It will be harder for drug companies to meet ICER's new COVID-19 pricing targets. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Market Access

More from Pink Sheet